The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities

Cécile Macé, Jean-Baptiste Nikiema, Omar Serigne Sarr, Patient Ciza Hamuli, Roland Djang'eing'a Marini, Richard Cizungu Neci, Pernette Bourdillon Esteve, Raffaella Ravinetto

Research output: Contribution to journalA1: Web of Science-articlepeer-review


Assuring the quality of medical products manufactured, imported or distributed in francophone sub-Saharan Africa remains a challenge, despite positive signals like the growing engagement in the benchmarking of regulatory authorities and -particularly- in the establishment of the African Medicines Agency. In this short report, we describe the existing activities to prevent, detect and respond to substandard and falsified products (SF) in this region, either through African multilateral organizations and initiatives led by the World Health Organization, or through the contribution of other stakeholders, such as local universities and procurement agencies. We underline that these emerging local stakeholders may play a pivotal role to guide and inform the national regulatory authorities about the prevalence and patterns of SF medical products, complementing the market surveillance and control, and building awareness of the importance of pharmaceutical quality assurance for public health.

Original languageEnglish
Article number117
JournalJournal of Pharmaceutical Policy and Practice
Number of pages4
Publication statusPublished - 2023

Cite this